Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.54 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.54 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2634370 | 0.81 | KCNK3 (0.66) | NPC1KCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL6168406 | 0.81 | NPC1 (0.48) | NPC1KCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL16250691 | 0.77 | NPC1 (0.62) | NPC1KCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL12434450 | 0.75 | KCNK3 (0.73) | NPC1KCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL27521914 | 0.75 | HPGD (0.50) | NPC1KCNA5ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5862101 | 0.74 | NPC1 (1.00) | NPC1ALDH1A1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL28497417 | 0.74 | NPC1 (1.00) | NPC1ALDH1A1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL16234809 | 0.74 | NPC1 (0.58) | NPC1KCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL16234810 | 0.74 | NPC1 (0.58) | NPC1KCNK3KCNK5KCNA5KCNK17 | |
| SCHEMBL12434091 | 0.73 | KCNK3 (0.67) | NPC1KCNK3KCNK5KCNA5KCNK17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924392-B2 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-02 | — | — | US | disclosed |
| US-20030225099-A1 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-04 | — | — | US | disclosed |
| US-6605625-B2 | Antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-12 | — | — | US | disclosed |
| US-20030013719-A1 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225099-A1 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | PON1, CYP3A43, KCNH1 | NPC1 340/4885KCNK3 143/4885KCNK5 127/4885 |
| US-20030013719-A1 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | PON1, CYP3A43, KCNH1 | NPC1 340/4885KCNK3 143/4885KCNK5 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.